Livraison suivie dans le monde entier | Env. 9–14 jours ouvrés

Votre panier

Votre panier est vide

Commencer à parcourir

Livraison gratuite pour les commandes de plus de €500.

Sous-total€0
Passer à la caisse
MétaboliqueClinique

Retatrutide

Recherche publiée et base de preuves

Retatrutide (LY3437943) is an investigational single-peptide triple agonist of the GIP, GLP-1 and glucagon receptors, first described in preclinical rodent pharmacology and phase 1 studies in 2022 and subsequently in phase 2 randomised trials in obesity, type 2 diabetes and metabolic dysfunction-associated steatotic liver disease. Phase 2 reports documented dose-dependent reductions in body weight, HbA1c and liver fat content, alongside predominantly gastrointestinal adverse events. A registrational phase 3 programme (TRIUMPH) and a separate TRANSCEND programme in type 2 diabetes and chronic kidney disease followed; the first phase 3 readout (TRANSCEND-T2D-1) was published in The Lancet in 2026, and the 80-week TRIUMPH-1 (obesity without diabetes) and TRIUMPH-2 (obesity with type 2 diabetes) trials were published in September 2026, reporting larger mean weight reductions than placebo with predominantly gastrointestinal adverse events. As of October 2026 the compound was not an approved medicine in any jurisdiction.

En bref
  • Le retatrutide est un agoniste triple des récepteurs GIP, GLP-1 et glucagon.
  • Des essais humains ont rapporté des réductions dose-dépendantes du poids et de l'HbA1c.
  • La sécurité à long terme et les résultats cardiovasculaires ne sont pas établis.

23 études · 21 depuis 2023 · plus récente 2026

Études citées
23
Publiées 2023+
21
Article le plus récent
2026
Dernière révision
oct. 2026

Thèmes récurrents dans la littérature

  • GIP/GLP-1/glucagon triple receptor agonism as a single peptide
  • Dose-dependent body-weight reduction in phase 2 obesity trials
  • Glycaemic control in type 2 diabetes
  • Hepatic steatosis and MASLD liver fat content
  • Body composition: fat mass versus lean mass partitioning
  • Cardiometabolic biomarkers, lipoproteins and blood pressure
  • Renal endpoints (UACR, eGFR) and the TRANSCEND-CKD mechanistic trial
  • Appetite and eating-behaviour endpoints
  • Gastrointestinal tolerability and dose escalation
  • Phase 3 registrational programme design (TRIUMPH basket trials)

Identifiants du composé

Les preuves

23 études publiées.

Classées par rigueur du protocole d'étude, puis par date. Chaque entrée renvoie à sa source pour que les résultats puissent être vérifiés dans l'article plutôt que pris sur parole.

  1. 01Revue systématique2026

    Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials

    Simental-Mendia LE, et al. · High Blood Pressure & Cardiovascular Prevention · systematic review and meta-analysis of randomised controlled trials of retatrutide

    Pooled analysis reported a reduction in systolic blood pressure (weighted mean difference -6.79 mmHg). Total cholesterol fell by 21.88 mg/dL, LDL cholesterol by 13.10 mg/dL and triglycerides by 40.90 mg/dL.

  2. 02Revue systématique2026

    Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.

    Nong K, et al. · BMJ · network meta-analysis, 262 RCTs, n=99791, 19 drugs

    Retatrutide, mazdutide and ecnoglutide were estimated to produce weight reductions of 13.1-14.6% versus lifestyle modification at one year, but with very low to low certainty. Tirzepatide and semaglutide had moderate to high certainty evidence for weight loss.

  3. 03Revue systématique2025

    Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials

    Misra S, et al. · Journal of Basic and Clinical Physiology and Pharmacology · systematic review of 3 clinical trials, 691 randomised participants, mean age 54.3 years

    The review reported that the 12 mg dose was associated with the largest weight reductions and metabolic changes across the included trials. Gastrointestinal events were the most frequently reported adverse effects.

  4. 04Clinique humaine2026

    Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials

    Giblin K, et al. · Diabetes, Obesity & Metabolism · design paper for four phase 3 randomised, double-blind, placebo-controlled trials, more than 5,800 participants

    The paper described the TRIUMPH programme: TRIUMPH-1 and TRIUMPH-2 as weight-management basket trials with nested obstructive sleep apnoea and osteoarthritis protocols, TRIUMPH-3 in participants with established cardiovascular disease, and TRIUMPH-4 as a standalone knee osteoarthritis trial. It reported rationale and design only; outcome data were not included.

  5. 05Clinique humaine2026

    Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease

    Heerspink HJL, et al. · Nephrology Dialysis Transplantation · phase 2b mechanistic trial design paper, n=146 randomised participants with chronic kidney disease

    The paper set out the design and baseline characteristics of a mechanistic trial whose primary endpoint was change in measured glomerular filtration rate by iohexol clearance from baseline to week 24. Primary outcome data were not reported.

  6. 06Clinique humaine2026

    Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial

    Bajaj HS, et al. · The Lancet · phase 3 double-blind randomised trial, n=537 adults with type 2 diabetes, 40 weeks

    Mean change from baseline in HbA1c was -1.69% with retatrutide 4 mg versus -0.81% with placebo, with treatment differences across doses ranging from -0.88% to -1.12% (all P < 0.0001). This was the first published phase 3 readout for the compound.

  7. 07Clinique humaine2026

    Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes

    Ruotolo G, et al. · Diabetes, Obesity & Metabolism · biomarker analyses of two phase 2 randomised, double-blind, placebo-controlled trials (36 and 48 weeks)

    Non-HDL cholesterol fell by up to 26.9% and apolipoprotein B by up to 24.2%. Large triglyceride-rich lipoprotein particle concentrations declined by up to 84.4%.

  8. 08Clinique humaine2026

    Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity.

    Jastreboff AM, et al. · N Engl J Med · phase 3 RCT (TRIUMPH-1), n=2339, 80 weeks, adults with obesity without diabetes

    Mean body-weight change was -17.6% to -25.0% across retatrutide groups versus -3.9% with placebo. In subgroups, retatrutide reduced knee osteoarthritis pain scores (n=574) and the apnoea-hypopnoea index in obstructive sleep apnoea (n=243) more than placebo. Gastrointestinal events were the most common adverse events.

  9. 09Clinique humaine2026

    Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial.

    Bellido V, et al. · Lancet · phase 3 RCT (TRIUMPH-2), n=1152, 80 weeks, obesity with type 2 diabetes

    Mean body-weight change was -11.9% to -18.8% across retatrutide groups versus -5.1% with placebo, with improved glycaemic control. Diarrhoea, nausea, hypotension and dysesthesia were more frequent with retatrutide, and discontinuation due to adverse events was higher in the two upper dose groups than with placebo.

    Résultat de sécurité signalé. Hypotension and dysesthesia occurred more often with retatrutide than placebo, alongside higher gastrointestinal event rates.

  10. 10Clinique humaine2026

    Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea.

    Grunstein RR, et al. · N Engl J Med · two phase 3 double-blind placebo-controlled trials nested within the TRIUMPH-1 and TRIUMPH-2 basket trials (TRIUMPH-1-OSA n=243 without diabetes; TRIUMPH-2-OSA n=448 with type 2 diabetes), adults with moderate-to-severe obstructive sleep apnoea and BMI of at least 27, 80 weeks

    At 80 weeks the apnoea-hypopnoea index fell by 22.9 to 34.3 events per hour across retatrutide dose groups in TRIUMPH-1-OSA versus 9.9 with placebo, and by 19.2 to 25.4 versus 10.3 in TRIUMPH-2-OSA, with all placebo-adjusted differences favouring retatrutide. Body weight fell by 12.5% to 22.2% and 12.1% to 18.5% respectively versus 4.8% and 5.6% with placebo, and gastrointestinal events were the most common adverse events.

  11. 11Clinique humaine2026

    Retatrutide and lipid and metabolite profiles in participants with obesity with or without type 2 diabetes.

    Pearson MJ, et al. · J Clin Endocrinol Metab · post hoc metabolomic and lipidomic analysis of two randomised placebo-controlled phase 2 trials, 282 participants with obesity (48 weeks) and 213 with type 2 diabetes (36 weeks)

    Higher retatrutide doses were associated with changes in a cluster of fatty-acid-oxidation metabolites (3-hydroxybutyrate, acetylcarnitine, free carnitine and long-chain acylcarnitines) and in metabolites linked to insulin resistance, including branched-chain amino acids, in both populations. In mediation analyses the fatty-acid-oxidation biomarkers accounted for 23.2% of the weight-reduction response in participants without type 2 diabetes and 12.7% in those with it.

  12. 12Clinique humaine2026

    Accelerating Use of Unapproved Retatrutide Is Associated with Weaker Weight Loss and Increased Cardiovascular Symptoms

    Murugadoss K, et al. · Preprints.org · preprint (not peer reviewed): retrospective cohort in a US federated electronic health record network, 652 patients with confirmed exposure to products described as retatrutide; matched analysis of 89 trial participants (retatrutide or placebo) and 243 users of compounded retatrutide against semaglutide and tirzepatide initiators

    Users of compounded retatrutide lost 7.2% of body weight at 6-12 months versus 15.5% in the trial cohort (P=0.004), similar to matched tirzepatide users (7.7%). Heart rate rose at 3 months in the trial cohort (+4.3 beats per minute) and the compounded cohort (+2.5) but not in matched semaglutide or tirzepatide users, and the pooled retatrutide cohort had more new cardiovascular (RR 1.56) and neuropsychiatric (RR 1.95) symptoms; differences in major adverse cardiovascular events were not statistically significant.

    Résultat de sécurité signalé. Heart-rate rise and more new cardiovascular and neuropsychiatric symptoms than in matched semaglutide and tirzepatide users, in a preprint cohort that included non-trial products of unverified content.

  13. 13Clinique humaine2025

    Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial

    Coskun T, et al. · The Lancet Diabetes & Endocrinology · phase 2 body-composition substudy, n=189 adults with type 2 diabetes, 36 weeks

    Total fat mass decreased 23.2% with retatrutide 12 mg, a least-squares mean difference of -18.7% versus placebo. The substudy characterised the relative contribution of fat and lean tissue to total weight change.

  14. 14Clinique humaine2025

    The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and Obesity

    Heerspink HJL, et al. · Kidney International Reports · post-hoc analysis of two phase 2 RCTs, n=281 (type 2 diabetes, 36 weeks) and n=338 (obesity, 48 weeks)

    Urine albumin-to-creatinine ratio fell 37.0% with retatrutide 12 mg in the type 2 diabetes trial. Estimated GFR rose by 8.5 ml/min/1.73 m2 in the obesity trial.

  15. 15Clinique humaine2025

    Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study

    Kanu C, et al. · Diabetes, Obesity & Metabolism · phase 2 RCT patient-reported-outcome analysis, n=275 adults with type 2 diabetes, placebo and dulaglutide comparators

    Higher retatrutide doses were associated with greater reductions from baseline in overall appetite, hunger and prospective food consumption. Changes in these ratings correlated with observed weight loss.

  16. 16Clinique humaine2024

    Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial

    Sanyal AJ, et al. · Nature Medicine · phase 2a randomised, double-blind, placebo-controlled sub-study, n=98 adults with MASLD, 48 weeks

    Relative liver fat content declined in a dose-dependent manner at 24 weeks: -42.9% (1 mg), -57.0% (4 mg), -81.4% (8 mg) and -82.4% (12 mg) versus +0.3% with placebo. All active-dose comparisons versus placebo were reported as P < 0.001.

  17. 17Clinique humaine2023

    Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial

    Jastreboff AM, et al. · The New England Journal of Medicine · phase 2 randomised, double-blind, placebo-controlled trial, n=338 adults with obesity, 48 weeks

    At 48 weeks the least-squares mean percentage change in body weight was -24.2% in the 12 mg group compared with -2.1% with placebo. Adverse events were predominantly gastrointestinal and dose-related.

  18. 18Clinique humaine2023

    Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA

    Rosenstock J, et al. · The Lancet · phase 2 placebo- and dulaglutide-controlled RCT, n=281 adults with type 2 diabetes, 36 weeks

    HbA1c change at 24 weeks was -2.02% with retatrutide 12 mg versus -0.01% with placebo. Body weight fell 16.94% at 36 weeks in the 12 mg group compared with 3.00% with placebo.

  19. 19Clinique humaine2022

    LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial

    Urva S, et al. · The Lancet · phase 1b multiple-ascending-dose RCT, n=72 adults with type 2 diabetes, 12 weeks

    Multiple ascending doses were administered over 12 weeks in adults with type 2 diabetes. Placebo-adjusted body-weight reduction reached -8.96 kg in the highest-dose cohort, and HbA1c fell significantly in the three highest-dose cohorts.

  20. 20Animal in vivo2026

    Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models

    Briand F, et al. · Obesity (Silver Spring) · diet-induced obese mouse and hamster models of MASH

    In the mouse model retatrutide reduced body weight by 31% versus vehicle (P < 0.0001) and lowered hepatic steatosis scores. Insulin resistance measured by HOMA-IR was also reduced.

  21. 21Animal in vivo2022

    LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept

    Coskun T, et al. · Cell Metabolism · in vitro receptor pharmacology plus diet-induced obese mice and rats, with a phase 1 single-ascending-dose cohort

    The report characterised LY3437943 as a single peptide with balanced agonism at the glucagon, GIP and GLP-1 receptors. In obese rodents it reduced body weight and improved glycaemic control, with the effect attributed to both reduced calorie intake and increased energy expenditure.

  22. 22Rapport de cas2026

    Emerging risks of health optimisation: refractory nausea associated with peptide injections reported to contain retatrutide.

    Buzzi RM, Huber LC · BMJ Case Rep · single case report, woman in her mid-20s given subcutaneous injections of an unverified product reported to contain retatrutide in a wellness setting by a non-medical practitioner

    She presented with 5 days of persistent nausea, repeated vomiting, loose stools and markedly reduced oral intake; investigations found no alternative cause and symptoms persisted despite several antiemetics. Symptoms improved 2 days after admission and resolved within 1 week, and the Naranjo score of 7 indicated probable causality.

    Résultat de sécurité signalé. Refractory nausea and vomiting requiring hospital admission, with probable causality (Naranjo score 7), after injections of an unverified product reported to contain retatrutide.

  23. 23Rapport de cas2026

    Online-Sourced Retatrutide Complicating Impending Diabetic Ketoacidosis in a Patient With Type 1 Diabetes and Concurrent Shigella Gastroenteritis.

    Branine N · Cureus · single case report, man in his mid-30s with longstanding type 1 diabetes who self-administered an online-purchased product marketed as retatrutide

    He developed severe vomiting, diarrhoea, hyperglycaemia, ketonaemia peaking at 4.3 mmol/L and acute kidney injury, needing intravenous insulin and fluids, and recovery was complicated by recurrent hypoglycaemia; diabetic ketoacidosis did not develop. Stool culture grew Shigella flexneri and his partner, who took the same preparation, also had gastrointestinal symptoms; the author stated that causation could not be established.

    Résultat de sécurité signalé. Impending ketoacidosis with acute kidney injury and later recurrent hypoglycaemia in a person with type 1 diabetes after an online-purchased product marketed as retatrutide, with concurrent Shigella infection.

Limites

Ce que ces preuves n'établissent pas.

Retatrutide remains investigational and unapproved; long-term safety, cardiovascular outcome data and durability of effect after discontinuation have not been established in published peer-reviewed reports. As of October 2026 only TRIUMPH-1 and TRIUMPH-2 had been published in full; the remaining TRIUMPH trials and the TRANSCEND-CKD programme had not reported peer-reviewed efficacy results, and published network meta-analyses rated the certainty of retatrutide weight-loss estimates as low to very low.

Questions courantes sur la recherche.

What is retatrutide?

Retatrutide (development code LY3437943) is an investigational synthetic peptide with agonist activity at the GIP, GLP-1, and glucagon receptors. It is studied in metabolic research and remains unapproved by any regulatory authority.

How does it differ from semaglutide and tirzepatide?

The three molecules target different receptor sets. Semaglutide is a single GLP-1 receptor agonist, tirzepatide a dual GIP/GLP-1 agonist, and retatrutide adds glucagon-receptor activity on top of GIP and GLP-1 — a triple-agonist profile described in the cited literature.

What have the phase 2 trials of retatrutide reported?

A 48-week phase 2 randomised, double-blind, placebo-controlled trial in 338 adults with obesity reported a least-squares mean change in body weight of -24.2 percent in the 12 mg group compared with -2.1 percent with placebo. A separate 36-week phase 2 trial in 281 adults with type 2 diabetes reported an HbA1c change of -2.02 percent at 24 weeks with 12 mg versus -0.01 percent with placebo, and a 16.94 percent fall in body weight at 36 weeks against 3.00 percent with placebo. Adverse events across the programme were predominantly gastrointestinal and dose-related.

Is retatrutide an approved medicine?

No. As of October 2026 retatrutide was not an approved medicine in any jurisdiction. Its phase 3 programme has begun to report: a 40-week trial in 537 adults with type 2 diabetes was published in 2026, and in September 2026 the 80-week TRIUMPH-1 trial in 2,339 adults with obesity and the TRIUMPH-2 trial in 1,152 adults with obesity and type 2 diabetes were published. Long-term safety, cardiovascular outcome data and durability of effect after discontinuation have not been established in peer-reviewed reports.

À des fins de recherche uniquement. Non destiné à la consommation humaine, au diagnostic, au traitement ou à la prévention de toute condition. Rien sur cette page ne constitue un avis médical, et aucune étude résumée ici ne doit être considérée comme une recommandation.